ReproNovo Funding News- Swiss HealthTech Startup ReproNovo Raises €57M To Tackle Declining Fertility Rates

The round was led by Jeito Capital, AXA IM, and M Ventures, with support from other healthcare investors like Ysios Capital and ALSA Ventures.

Jean Marie Duvall, Co-founder and CEO of ReproNovo, said: “We are focused on innovative therapeutic solutions for male and female infertility and pioneering management options for conditions like adenomyosis. Our aim is to address critical gaps in the landscape of infertility and women’s health worldwide. We are thrilled to announce the successful closing of our $65 million Series A funding round with this strong, sector specialised group of investors, marking a significant milestone in our journey to becoming a leading reproductive medicine and women’s health company.”

ReproNovo is led by Jean Marie Duvall (CEO), Joan-Carles Arce, MD, PhD (Chief Science and Medical Officer), and BingMei Hao (CFO), who all have strong experience in clinical development and product launches.

Read More - Aufinity Group Funding News- German FinTech Startup Aufinity Group Raises €23Mn Funding

Dr Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital, said: “ReproNovo combines strong innovative potential, a seasoned team, and a clear ambition to address one of the most pressing global challenges of our time: declining birth rates. At Jeito, we are committed to advancing breakthrough innovations with significant value for both patients and society. This investment reflects that commitment. We are proud to support the acceleration of ReproNovo’s clinical development and help unlock its potential to become a future market leader.”

Fertility rates are falling worldwide, with male infertility on the rise—sperm counts have dropped by 50% to 60% over the past 40 years. At the same time, women face serious health risks during fertility treatments.

These trends highlight the urgent need for new reproductive solutions that address the needs of both men and women.

Ksenija Pavletic, Partner and Chief Commercial Officer at Jeito Capital, added: “As approximately one in six people worldwide will face infertility issues, we are proud to support ReproNovo, whose commitment to advancing novel therapies in reproductive health aligns well with our focus on accelerating cutting-edge technologies and the commercialisation of treatments with transformative benefits for patients. We are highly impressed by the ReproNovo team, whose members have a strong track record in this field, having brought a number of compounds successfully through clinical development and onto the market. Their deep understanding of the field will enable them to effectively address critical unmet needs that have a strong impact on society.”

ReproNovo is headquartered in Lausanne, Switzerland, with its main development team based in Copenhagen, Denmark, and an additional site in Barcelona, Spain.

Alongside the funding news, Ksenija Pavletic—Partner and Chief Commercial Officer at Jeito, with 25 years of experience in reproductive medicine and women’s health—will join ReproNovo’s Board of Directors.

About ReproNovo

Founded in 2021, ReproNovo is creating new solutions to tackle key challenges in reproductive medicine and women’s health, such as male and female infertility and uterine health.